Cancer Genetics to Evaluate Biomarkers for Effector Therapeutics

Apr 10, 2017

|

NEW YORK (GenomeWeb) – Cancer Genetics said today that it has been hired by Effector Therapeutics to provide clinical biomarker services for Effector's lead product candidate, eFT508 — a highly selective oral small molecule inhibitor of MNK1 and MNK2.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Main menu